Recursion Pharmaceuticals Inc. stocks have been trading up by 4.8 percent after a major AI-driven drug discovery breakthrough.
Click Here for a Millionaire's POV on Trading RXRX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- A recent Form 4 filing disclosed changes in beneficial ownership of Recursion Pharmaceuticals (RXRX) securities by an insider.
- Another Form 4 filing reported a change in beneficial ownership of RXRX securities by an insider but did not specify who traded, the size of the transaction, or whether it was a purchase or sale.
- A separate Form 4 filing noted changes in insider beneficial ownership at Rex Therapeutics (RXRX), without clarifying whether the move was a purchase, sale, or equity award.
Live Update At 15:02:57 EDT: On Friday, September 18, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 4.8%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
RXRX has been grinding higher off late‑August levels, with the stock closing around $3.71 after trading in a tight $3.50–$3.72 band. For active traders, Recursion Pharmaceuticals is acting like a low‑priced biotech trying to base after a long slide, not a name in full breakout mode.
On the numbers, RXRX remains a classic high‑burn, early‑stage platform story. Quarterly revenue sits near $7.3M, but the company booked a net loss of about $131M and an EBITDA loss of roughly $112.5M for Q2 2026. That’s why return on equity and return on assets are deeply negative and why there is no meaningful P/E ratio for RXRX right now.
The balance sheet is the counterweight. Recursion Pharmaceuticals reported roughly $545.7M in cash and equivalents at 2026/06/30, a current ratio near 5, and very low debt, with total debt to equity about 0.07. For traders, that means RXRX has runway to keep funding research, but the price‑to‑sales ratio near 31 shows the market is already paying a big premium for future potential, not present profits.
More Breaking News
- MSTR Stock Rallies As Bitcoin Resurgence Meets Wall Street Upgrades
- EQPT Stock Falls As EquipmentShare.com Faces Securities Class Actions
- Sandisk Stock Surges As S&P 100 Inclusion Fuels Momentum
- LRCX Rises As Lam Research Wins Higher Targets And Boosts Dividend
Intraday, RXRX traded in an unusually tight $3.51–$3.72 range, with a slow, steady bid all day. That’s the kind of tape where momentum scalpers watch for sudden volume spikes around key headlines like these Form 4s.
Why Traders Are Watching RXRX Insider Filings
RXRX is back on scanners because of a series of fresh Form 4 filings. On 2026/09/16, Recursion Pharmaceuticals reported a change in beneficial ownership of RXRX by an insider. The filing doesn’t tell traders whether that insider bought shares, sold shares, or just had an award vest. There’s no size, no name, no clear signal. But it does confirm management‑level activity around this price zone.
Earlier, on 2026/09/02, another Form 4 also logged a change in RXRX beneficial ownership with the same problem: no clarity on direction or magnitude. For short‑term trading, that matters. A large insider buy near $3 is very different from a small programmed sale, yet the market doesn’t get that detail from these summaries.
Adding to the noise, a third Form 4 on 2026/09/10 flagged insider beneficial ownership changes at Rex Therapeutics, which also uses the RXRX ticker. That’s a trap for anyone skimming headlines. Recursion Pharmaceuticals and Rex Therapeutics are different companies, and mixing their Form 4s can distort sentiment and trigger bad trades.
For disciplined traders, the lesson is simple. RXRX headlines right now are more about activity than direction. The filings confirm insiders are engaged, but they do not confirm bullish conviction or quiet distribution. In a stock like Recursion Pharmaceuticals, where the chart shows a slow grind off lows and fundamentals show heavy cash burn, that kind of ambiguous insider data should be a supporting factor, not the main driver of a trading thesis.
Conclusion
RXRX is sitting in an interesting spot for active traders. Recursion Pharmaceuticals has a big cash pile, limited debt, and a long runway, but it’s also running steep losses and trading at a rich sales multiple. The chart shows RXRX holding above $3.30 and pushing into the high $3s on relatively contained intraday volatility. That’s constructive, but not explosive.
The recent Form 4 filings do not change that big picture. They show insiders at RXRX and at similarly‑ticked Rex Therapeutics moving stock around, but without clear buy‑or‑sell labels, the filings are more noise than signal. Smart traders treat them as a reminder to watch the tape, not as a green or red light by themselves.
For anyone studying RXRX, the edge will come from marrying this kind of regulatory detail with price, volume, and broader biotech sentiment. As Tim Sykes likes to say, “Patterns repeat, but only for the traders who put in the work to see them.” And in the same spirit of disciplined trading, As Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.”. Recursion Pharmaceuticals will keep printing headlines and filings. The real question is whether traders are prepared, with a plan, when RXRX finally breaks out of this tight range.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.